Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Recently, a retrospective study reported the efficacy and safety of modified gemcitabine plus
nab-paclitaxel (GnP), which were administered biweekly (on days 1 and 15). With 79 patients
of metastatic pancreatic cancer, this study reported similar efficacy and improved toxicity
profile compared with standard dose GnP (OS 10 months, PFS 5.4 months, Grade ≥3 Neutropenia
19%, Grade ≥3 sensory neuropathy 1.6%). Also, several studies reported that dose reduction of
nab-paclitaxel in breast or pancreatic cancer treatment was not related of decreased
survival, or related with prolonged survival and increased treatment exposure. However, this
finding need to be evaluated in prospective clinical trial.
This phase II trial will evaluate the efficacy and safety of modified GnP, which omit the day
8 administration of nab-paclitaxel, in metastatic pancreatic cancer.